Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 13/20 | 0.86 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3198777 | 0.93 | GPR52 (1.00) | GPR52SNCALMNAMAPTTP53 | |
| SCHEMBL29452903 | 0.93 | GPR52 (1.00) | GPR52SNCALMNAMAPTTP53 | |
| SCHEMBL3213566 | 0.90 | GPR52 (0.85) | GPR52SNCAS1PR4S1PR5TP53 | |
| SCHEMBL3197888 | 0.88 | GPR52 (0.81) | GPR52 | |
| SCHEMBL3220886 | 0.88 | GPR52 (0.81) | GPR52SNCAS1PR4S1PR5LMNA | |
| Hydrochloric Acid SCHEMBL1851153 | 0.87 | GPR52 (0.80) | GPR52SNCAS1PR4S1PR5LMNA | |
| SCHEMBL3218938 | 0.86 | GPR52 (0.88) | GPR52S1PR4S1PR5 | |
| SCHEMBL3204292 | 0.86 | GPR52 (0.88) | GPR52S1PR4S1PR5LMNAMAPT | |
| SCHEMBL3210142 | 0.86 | GPR52 (0.87) | GPR52S1PR4LMNAMAPTTP53 | |
| SCHEMBL13489634 | 0.86 | GPR52 (0.78) | GPR52SNCAKIFC1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885SNCA 2055/4885KIFC1 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.